Skip to content

Clinical study to compare the efficacy New Rheumatil Gel with Diclofenac Gel in osteoarthritis and other muscloskeletal condition.

Open, prospective labeled clinical study to evaluate & compare the efficacy of New Rheumatil Gel with Diclofenac Gel in osteoarthritis and other muscloskeletal condition.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/011783
Enrollment
100
Registered
2018-02-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M150- Primary generalized (osteo)arthritis

Interventions

Intervention1: Test item contains Mahanaryan tail 5.0 parts Vishgarbh tail 1.95 parts Pudina satva 1.4 parts Karpur 0.35 parts Gandhpura tail 0.2 parts Cajeput oil 0.2 parts Katuveera satva 0.1 parts:

Sponsors

Dabur India Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or Female patients between 30-60 years of age. Adult patients of both the sexes. 2. Patients suffering from mild to moderate OA involving knee joint. 3. The symptoms may consist of pain, swelling, tenderness and morning stiffness, of one or more joints, which may have lasted for > 2 weeks. 4. Patients willing to participate in the study and willing to sign Informed Consent Form 5. Patients on any other local medication for symptomatic management of joint pains shall be included in the study after an adequate washout period of 7 day. 6. Any other musculo-skeletal disorders with pain as the major presenting symptom.

Exclusion criteria

Exclusion criteria: 1. Patients with serious medical illness (HIV, Diabetes, SLE, Rheumatoid Arthritis, Rheumatic Fever, Psoriatic Arthritis), surgical illness where compliance is difficult. 2. Patients taking part in any other study. 3. Patients on any other medication for the treatment of arthritis other than specified in the study.

Design outcomes

Primary

MeasureTime frame
2 weeks usage of the formulation with or without relief from the symptoms with 1 week follow-up.Timepoint: 7 days & 14 days

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactDr Arun Gupta

Dabur India Limited

arun.gupta@dabur.com919910200255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026